Efficacy analysis of targeted P53 therapy in solid tumors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mutations in the p53 oncogene are prevalent in most carcinomas and frequently inactivated in specific tumors, leading to poor patient prognosis.
• The prevailing view considered targeting p53 protein unfeasible, but recent research challenges this notion.

Purpose of the Study:

• To provide a comprehensive overview of the latest targeted drugs for solid tumors based on p53 status.
• To analyze the efficacy of these drugs in patients and explore reasons for variable treatment outcomes.

Main Methods:

• Literature review of recent advancements in p53-targeted therapies.
• Analysis of clinical data on drug efficacy in solid tumors with different p53 mutations.
• Exploration of mechanisms underlying drug response and resistance.

Main Results:

• Emerging strategies include restoring wild-type p53 function, degrading mutant p53, and modulating immune and metabolic responses.
• Several targeted drugs show promise in controlling tumor progression in diverse p53 states.
• Factors influencing drug efficacy, including specific p53 mutations and tumor microenvironment, are being identified.

Conclusions:

• Targeting p53, despite historical challenges, presents a viable therapeutic avenue for solid tumors.
• Further research into drug efficacy and resistance mechanisms is crucial for optimizing p53-targeted cancer treatments.